{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:21:58Z","timestamp":1794997318779,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04821-4","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:55:33Z","timestamp":1771671333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Veverimer in treating metabolic acidosis in chronic kidney disease patients: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Muhammad","family":"Islampanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Noradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Tafazolimoghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Pirzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"4821_CR1","doi-asserted-by":"crossref","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","DOI":"10.1016\/j.kisu.2021.11.003"},{"issue":"10225","key":"4821_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBDCKD Collaboration","year":"2020","unstructured":"Collaboration GBDCKD. Global, regional, and National burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"7","key":"4821_CR3","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney Disease - A systematic review and Meta-Analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"},{"issue":"2","key":"4821_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5049\/EBP.2021.19.2.29","volume":"19","author":"HJ Kim","year":"2021","unstructured":"Kim HJ. Metabolic acidosis in chronic kidney disease: Pathogenesis, clinical Consequences, and treatment. Electrolyte Blood Press. 2021;19(2):29\u201337.","journal-title":"Electrolyte Blood Press"},{"issue":"6","key":"4821_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1159\/000516371","volume":"7","author":"M Adamczak","year":"2021","unstructured":"Adamczak M, Surma S. Metabolic acidosis in patients with CKD: Epidemiology, Pathogenesis, and treatment. Kidney Dis (Basel). 2021;7(6):452\u201367.","journal-title":"Kidney Dis (Basel)"},{"issue":"3","key":"4821_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1681\/ASN.2019070677","volume":"31","author":"DE Wesson","year":"2020","unstructured":"Wesson DE, Buysse JM, Bushinsky DA. Mechanisms of metabolic Acidosis-Induced kidney injury in chronic kidney disease. J Am Soc Nephrol. 2020;31(3):469\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4821_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.ajkd.2009.02.014","volume":"54","author":"SN Shah","year":"2009","unstructured":"Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease: A cohort study. Am J Kidney Dis. 2009;54(2):270\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4821_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1159\/000339329","volume":"35","author":"P Susantitaphong","year":"2012","unstructured":"Susantitaphong P, Sewaralthahab K, Balk EM, Jaber BL, Madias NE. Short-and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol. 2012;35(6):540\u20137.","journal-title":"Am J Nephrol"},{"issue":"7","key":"4821_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2215\/CJN.13091118","volume":"14","author":"SD Navaneethan","year":"2019","unstructured":"Navaneethan SD, Shao J, Buysse J, Bushinsky DA. Effects of treatment of metabolic acidosis in CKD: a systematic review and Meta-Analysis. Clin J Am Soc Nephrol. 2019;14(7):1011\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4821_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.xkme.2020.12.006","volume":"3","author":"ML Melamed","year":"2021","unstructured":"Melamed ML, Raphael KL. Metabolic acidosis in CKD: A review of recent findings. Kidney Med. 2021;3(2):267\u201377.","journal-title":"Kidney Med"},{"key":"4821_CR11","doi-asserted-by":"publisher","first-page":"643128","DOI":"10.3389\/fphar.2021.643128","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Li L, Zhang X, Dong H, Lu M. Efficacy and safety of veverimer in the treatment of metabolic acidosis caused by chronic kidney disease: A Meta-analysis. Front Pharmacol. 2021;12:643128.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4821_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2215\/CJN.07300717","volume":"13","author":"DA Bushinsky","year":"2018","unstructured":"Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, et al. Randomized, controlled trial of TRC101 to increase serum bicarbonate in patients with CKD. Clin J Am Soc Nephrol. 2018;13(1):26\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4821_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2020.07.019","volume":"76","author":"HJ Adrogu\u00e9","year":"2020","unstructured":"Adrogu\u00e9 HJ, Madias NE. Veverimer: an emerging potential treatment option for managing the metabolic acidosis of CKD. Am J Kidney Dis. 2020;76(6):861\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"10179","key":"4821_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(18)32562-5","volume":"393","author":"DE Wesson","year":"2019","unstructured":"Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet. 2019;393(10179):1417\u201327.","journal-title":"Lancet"},{"issue":"10196","key":"4821_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0140-6736(19)31388-1","volume":"394","author":"DE Wesson","year":"2019","unstructured":"Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet. 2019;394(10196):396\u2013406.","journal-title":"Lancet"},{"issue":"4","key":"4821_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2215\/CJN.0000000000000119","volume":"18","author":"B Beynon-Cobb","year":"2023","unstructured":"Beynon-Cobb B, Louca P, Hoorn EJ, Menni C, Padmanabhan S. Effect of sodium bicarbonate on systolic blood pressure in CKD: A systematic review and Meta-Analysis. Clin J Am Soc Nephrol. 2023;18(4):435\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4821_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00424-024-02912-5","volume":"476","author":"C Kuhn","year":"2024","unstructured":"Kuhn C, Mohebbi N, Ritter A. Metabolic acidosis in chronic kidney disease: Mere consequence or also culprit? Pflugers Arch. 2024;476(4):579\u201392.","journal-title":"Pflugers Arch"},{"key":"4821_CR18","doi-asserted-by":"crossref","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n160"},{"key":"4821_CR19","doi-asserted-by":"crossref","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synthesis. 2023;21(3).","DOI":"10.11124\/JBIES-22-00430"},{"issue":"1","key":"4821_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"4821_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1681\/ASN.0000000000000292","volume":"35","author":"N Tangri","year":"2024","unstructured":"Tangri N, Mathur VS, Bushinsky DA, Klaerner G, Li E, Parsell D, et al. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled trial evaluating veverimer in slowing progression of CKD in patients with metabolic acidosis. J Am Soc Nephrol. 2024;35(3):311\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"4821_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1681\/ASN.20203110S1721e","volume":"31","author":"D Parsell","year":"2020","unstructured":"Parsell D, Guttendorf R, Stasiv Y, Li E, Klaerner G, Mathur VS. Action of veverimer on Gastrointestinal acid binding is not affected by Omeprazole. J Am Soc Nephrol. 2020;31:721\u20132.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4821_CR23","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ndt\/gfab209","volume":"37","author":"VS Mathur","year":"2022","unstructured":"Mathur VS, Li E, Wesson DE. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial. Nephrol Dial Transpl. 2022;37(7):1302\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"4821_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/ndt\/gfaa142.P0009","volume":"35","author":"J Shao","year":"2020","unstructured":"Shao J, Parsell D, Guttendorf R, Sen Wu Y, Tsao L, Tabakman S, et al. Evaluation of the potential for drug interactions with veverimer. Nephrol Dial Transpl. 2020;35:306.","journal-title":"Nephrol Dial Transpl"},{"key":"4821_CR25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1681\/ASN.2019070749","volume":"30","author":"DE Wesson","year":"2019","unstructured":"Wesson DE, Mathur VS, Tangri N, Stasiv Y, Parsell D, Li E, et al. Randomized controlled trial of long-term safety and efficacy of veverimer for treatment of metabolic acidosis. J Am Soc Nephrol. 2019;30:234.","journal-title":"J Am Soc Nephrol"},{"key":"4821_CR26","first-page":"91","volume":"28","author":"DA Bushinsky","year":"2017","unstructured":"Bushinsky DA, Hostetter TH, Alpern RJ, Klaerner G, Stasiv Y, Lockey C, et al. TRC101, a novel hydrochloric acid binder, increases serum bicarbonate in acidemic patients with CKD. J Am Soc Nephrol. 2017;28:91.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4821_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1124\/dmd.121.000366","volume":"49","author":"D Parsell","year":"2021","unstructured":"Parsell D, Shao J, Guttendorf R, Mathur V, Li E, Wu YS, et al. Assessment of the potential for veverimer Drug-Drug interactions. Drug Metab Dispos. 2021;49(7):490\u2013500.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"4821_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/j.ajkd.2020.02.060","volume":"75","author":"D Bushinsky","year":"2020","unstructured":"Bushinsky D, Mathur V, Wesson D. Mechanism of action and onset of effect of Veverimer, a novel acid binder for the treatment of metabolic acidosis associated with chronic kidney disease (CKD). Am J Kidney Dis. 2020;75(4):552\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"4821_CR29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.21037\/atm-20-3320","volume":"8","author":"AR Gone","year":"2020","unstructured":"Gone AR, Chen W. Veverimer for treatment of chronic metabolic acidosis in patients with chronic kidney disease. Ann Transl Med. 2020;8(22):1539.","journal-title":"Ann Transl Med"},{"issue":"4","key":"4821_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1053\/j.ajkd.2020.02.004","volume":"75","author":"M Abramowitz","year":"2020","unstructured":"Abramowitz M, Mathur V. CKD as a model of accelerated aging and improvement in physical function with investigational product veverimer. Am J Kidney Dis. 2020;75(4):536.","journal-title":"Am J Kidney Dis"},{"key":"4821_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1681\/ASN.20203110S1531d","volume":"31","author":"VS Mathur","year":"2020","unstructured":"Mathur VS, Walker M, Klaerner G. Correlation between patient-reported physical limitation and objective physical performance on the repeated chair stand test among patients with non-dialysis dependent CKD and metabolic acidosis. J Am Soc Nephrol. 2020;31:531\u20132.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4821_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.xkme.2021.03.016","volume":"3","author":"N Tangri","year":"2021","unstructured":"Tangri N, Li E, Mathur V. Effects of veverimer in older adults with CKD and metabolic acidosis. Kidney Med. 2021;3(4):689\u201391.","journal-title":"Kidney Med"},{"key":"4821_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1681\/ASN.20203110S1531b","volume":"31","author":"DE Wesson","year":"2020","unstructured":"Wesson DE, Mathur VS, Tangri N, Stasiv Y, Parsell D, Li E, et al. Effects of veverimer on serum bicarbonate and physical function in elderly patients with metabolic acidosis in CKD. J Am Soc Nephrol. 2020;31:531.","journal-title":"J Am Soc Nephrol"},{"key":"4821_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/ndt\/gfaa142.P0001","volume":"35","author":"DE Wesson","year":"2020","unstructured":"Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al. Effects of veverimer on serum bicarbonate and physical function in patients with chronic kidney disease and metabolic acidosis are independent of albuminuria: subgroup analyses from a randomized trial. Nephrol Dial Transpl. 2020;35:298.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4821_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.ajkd.2020.02.404","volume":"75","author":"D Wesson","year":"2020","unstructured":"Wesson D, Mathur V, Tangri N, Parsell D, Stasiv Y, Li E, et al. Effects of veverimer on serum bicarbonate and physical function in patients with congestive heart failure and chronic kidney disease: subgroup analysis from a randomized trial. Am J Kidney Dis. 2020;75(4):653\u20134.","journal-title":"Am J Kidney Dis"},{"key":"4821_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1681\/ASN.20203110S1352d","volume":"31","author":"DE Wesson","year":"2020","unstructured":"Wesson DE, Mathur VS, Tangri N, Stasiv Y, Parsell D, Li E, et al. Effects of veverimer on serum bicarbonate and physical function in patients with diabetes and CKD: subgroup analysis from a randomized trial. J Am Soc Nephrol. 2020;31:352\u20133.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4821_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12882-022-02690-1","volume":"23","author":"VS Mathur","year":"2022","unstructured":"Mathur VS, Wesson DE, Tangri N, Li E, Bushinsky DA. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial. BMC Nephrol. 2022;23(1):82.","journal-title":"BMC Nephrol"},{"key":"4821_CR38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1681\/ASN.20203110S1792a","volume":"31","author":"VS Mathur","year":"2020","unstructured":"Mathur VS, Wesson DE, Tangri N, Stasiv Y, Parsell D, Li E, et al. Effects of veverimer on serum bicarbonate and physical function in women with CKD: A subgroup analysis from a randomized controlled trial. J Am Soc Nephrol. 2020;31:792.","journal-title":"J Am Soc Nephrol"},{"key":"4821_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1681\/ASN.20203110S1649c","volume":"31","author":"DE Wesson","year":"2020","unstructured":"Wesson DE, Mathur VS, Tangri N, Stasiv Y, Parsell D, Li E, et al. No adverse effects of veverimer on volume status or blood pressure in patients with CKD and metabolic acidosis. J Am Soc Nephrol. 2020;31:649\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"4821_CR40","doi-asserted-by":"crossref","unstructured":"Tangri N, Walker M, Ferguson TW, Mathur V. Physical function in adults with metabolic acidosis and advanced CKD: patient reported versus assessed physical function. Kidney Med. 2022;4(9).","DOI":"10.1016\/j.xkme.2022.100518"},{"issue":"11","key":"4821_CR41","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/j.ekir.2021.08.015","volume":"6","author":"V Mathur","year":"2021","unstructured":"Mathur V, Li E, Bushinsky DA. Safety and efficacy of veverimer in acidotic patients with CKD and heart failure. Kidney Int Rep. 2021;6(11):2908\u201311.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4821_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00467-010-1564-4","volume":"26","author":"JA Kraut","year":"2011","unstructured":"Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol. 2011;26(1):19\u201328.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"4821_CR43","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.3390\/ijms25105187","volume":"25","author":"KL Raphael","year":"2024","unstructured":"Raphael KL. Metabolic acidosis in CKD: Pathogenesis, adverse effects, and treatment effects. Int J Mol Sci. 2024;25(10):5187.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4821_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/j.ackd.2017.06.005","volume":"24","author":"JA Kraut","year":"2017","unstructured":"Kraut JA, Madias NE. Adverse effects of the metabolic acidosis of chronic kidney disease. Adv Chronic Kidney Dis. 2017;24(5):289\u201397.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"4821_CR45","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/ndt\/gfs609","volume":"28","author":"KL Raphael","year":"2013","unstructured":"Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, Beddhu S. Serum bicarbonate and mortality in adults in NHANES III. Nephrol Dialysis Transplantation. 2013;28(5):1207\u201313.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"4","key":"4821_CR46","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1046\/j.1523-1755.2002.00276.x","volume":"61","author":"WP Pickering","year":"2002","unstructured":"Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int. 2002;61(4):1286\u201392.","journal-title":"Kidney Int"},{"issue":"4","key":"4821_CR47","doi-asserted-by":"publisher","first-page":"S1128","DOI":"10.3945\/ajcn.2010.28608B","volume":"91","author":"BT Workeneh","year":"2010","unstructured":"Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease123. Am J Clin Nutr. 2010;91(4):S1128\u201332.","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"4821_CR48","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1681\/ASN.2008111205","volume":"20","author":"I de Brito-Ashurst","year":"2009","unstructured":"de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075\u201384.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4821_CR49","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2215\/CJN.00380118","volume":"13","author":"J Kendrick","year":"2018","unstructured":"Kendrick J, Shah P, Andrews E, You Z, Nowak K, Pasch A, et al. Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD: a pilot randomized cross-over study. Clin J Am Soc Nephrol. 2018;13(10):1463\u201370.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4821_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2019.01.036","volume":"74","author":"KL Raphael","year":"2019","unstructured":"Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(2):263\u201375.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4821_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1124\/jpet.120.000190","volume":"375","author":"G Klaerner","year":"2020","unstructured":"Klaerner G, Shao J, Biyani K, Kade M, Kierstead P, Gbur R, et al. Mechanism of action of veverimer: a novel, orally administered, nonabsorbed, counterion-free, hydrochloric acid binder under development for the treatment of metabolic acidosis in chronic kidney disease. J Pharmacol Exp Ther. 2020;375(3):439\u201350.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4821_CR52","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJL Heerspink","year":"2012","unstructured":"Heerspink HJL, Holtkamp FA, Parving H-H, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82(3):330\u20137.","journal-title":"Kidney Int"},{"issue":"5","key":"4821_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MNH.0000000000000524","volume":"28","author":"W Chen","year":"2019","unstructured":"Chen W, Abramowitz MK. Advances in management of chronic metabolic acidosis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019;28(5):409\u201316.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"4821_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1124\/jpet.120.000190","volume":"375","author":"G Klaerner","year":"2020","unstructured":"Klaerner G, Shao J, Biyani K, Kade M, Kierstead P, Gbur R, et al. Mechanism of action of veverimer: A Novel, orally Administered, Nonabsorbed, Counterion-Free, hydrochloric acid binder under development for the treatment of metabolic acidosis in chronic kidney disease. J Pharmacol Exp Ther. 2020;375(3):439.","journal-title":"J Pharmacol Exp Ther"},{"key":"4821_CR55","doi-asserted-by":"publisher","unstructured":"Siddiqui AH, Batool F, Khan S, Rizvi SS, Usman S, Jawed H, et al. Safety and efficacy of sodium bicarbonate for treating metabolic acidosis in chronic kidney disease: A systematic review and meta-analysis. World J Nephrol. 2025;14(1):101078. https:\/\/doi.org\/10.5527\/wjn.v14.i1.101078","DOI":"10.5527\/wjn.v14.i1.101078"},{"key":"4821_CR56","doi-asserted-by":"publisher","unstructured":"Singh B, Tangri N, Chertow GM, Pergola PE, Turner SA, Kendrick JB, et al. Among patients meeting the KDIGO CKD practice point criterion for treatment of metabolic Acidosis, higher serum bicarbonate concentrations are associated with slower CKD progression: SA-PO496. J Am Soc Nephrol. 2024;35(10S). https:\/\/doi.org\/10.1681\/ASN.20249y7c86bc.","DOI":"10.1681\/ASN.20249y7c86bc"},{"key":"4821_CR57","unstructured":"Mount DB. Treatment and prevention of hyperkalemia in adults UpToDate: Wolters Kluwer; 2025 [updated February 5, 2024]."},{"issue":"5","key":"4821_CR58","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2215\/CJN.08340812","volume":"8","author":"MK Abramowitz","year":"2013","unstructured":"Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH. Effects of oral sodium bicarbonate in patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):714\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4821_CR59","volume-title":"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease","author":"CP Kovesdy","year":"2025","unstructured":"Kovesdy CP. Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease. Volume 8. UpToDate: Wolters Kluwer; 2025."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04821-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04821-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04821-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:03:52Z","timestamp":1771959832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04821-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4821"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04821-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6531618\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Veverimer effectively treats metabolic acidosis in chronic kidney disease, while also having similar side effects as the placebo group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Summary at a glance"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}